#United States #New York #Class Action #Pomerantz LLP #Replimune Group

Legal Alert: Join the Class Action Against Replimune Group, Inc.

Investors in Replimune Group, Inc. should take notice of a recent class action lawsuit filed against the company, as announced by Pomerantz LLP. This alert aims to inform those who have encountered financial losses in their investments with Replimune about their potential recourse through this legal avenue. If you bought or acquired Replimune securities during the relevant period, you might be eligible to become a Lead Plaintiff in this class action litigation.

Background of the Case

The lawsuit revolves around allegations that Replimune and some of its organizational leaders engaged in practices that resulted in securities fraud or other illegal business operations. Such allegations have significant implications, especially in light of a press release issued by Replimune on July 22, 2025, indicating that the U.S. Food and Drug Administration (FDA) had rejected the company's Biologics License Application for RP1—a treatment combination for advanced melanoma with nivolumab. The FDA’s decision not to approve the application due to insufficient evidence from the clinical trial known as the IGNYTE trial is central to the lawsuit’s claims. Investors should note that the FDA expressed concerns regarding the trial's design and its interpretation, emphasizing that it was not adequate to showcase substantial effectiveness, despite raising no safety issues.

As a result of the FDA's announcement, Replimune's stock took a severe hit, plunging by 77.24%—a staggering decline of $9.52 per share—closing at just $2.81 on that day. This sharp drop underlines the financial repercussions that stakeholders faced, accentuating the argument for investor protection and potential recovery through the class action lawsuit.

Next Steps for Investors

Investors affected by the recent downturn in Replimune's stock prices should act swiftly. The deadline to file your request to serve as Lead Plaintiff is September 22, 2025. Interested investors are encouraged to reach out to Danielle Peyton at Pomerantz LLP directly by calling 646-581-9980 or using the toll-free number 888.4-POMLAW. Additionally, email inquiries are welcome, with suggestions to include relevant personal information such as your mailing address and the number of shares purchased.

Why Join the Class Action?

Participating in a class action lawsuit can provide investors with several advantages, including:

• - Collective Action: Joining together with others who have experienced similar losses can strengthen the case against the defendants.
• - Cost Efficiency: Legal costs are typically shared among all members, reducing the individual financial burden.
• - Expert Representation: Established firms like Pomerantz LLP have a wealth of experience handling complex securities fraud cases, increasing the likelihood of a favorable outcome.

Engaging with Pomerantz LLP also provides access to resources and support from a legal team dedicated to fighting for the rights of investors who may have been misled or defrauded.

Conclusion

As one of the leading firms in corporate and securities litigation, Pomerantz LLP invites affected investors to consider their legal rights and take action. With the approaching deadline to join the class action against Replimune Group, it is essential to act promptly to secure your interests and seek potential compensation for your losses. For further details or to obtain a copy of the official complaint, you can visit Pomerantz's website at www.pomerantzlaw.com.